As it fights loom­ing com­pe­ti­tion on Sub­ox­one, In­di­v­ior gets FDA OK on new schiz­o­phre­nia drug

British drug­mak­er In­di­v­ior got the green light from US reg­u­la­tors to sell its schiz­o­phre­nia drug Perseris — a re­lief, no doubt, con­sid­er­ing the com­pa­ny’s on­go­ing ex­clu­siv­i­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER